LPL Financial LLC Has $2.19 Million Position in ADMA Biologics Inc $ADMA

LPL Financial LLC boosted its holdings in shares of ADMA Biologics Inc (NASDAQ:ADMA) by 84.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 110,253 shares of the biotechnology company’s stock after buying an additional 50,565 shares during the period. LPL Financial LLC’s holdings in ADMA Biologics were worth $2,187,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Cetera Investment Advisers boosted its stake in shares of ADMA Biologics by 1.3% in the 1st quarter. Cetera Investment Advisers now owns 50,511 shares of the biotechnology company’s stock valued at $1,002,000 after purchasing an additional 670 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in shares of ADMA Biologics by 1.1% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 66,671 shares of the biotechnology company’s stock valued at $1,323,000 after purchasing an additional 711 shares in the last quarter. GF Fund Management CO. LTD. boosted its stake in shares of ADMA Biologics by 21.9% in the 1st quarter. GF Fund Management CO. LTD. now owns 6,053 shares of the biotechnology company’s stock valued at $120,000 after purchasing an additional 1,089 shares in the last quarter. Journey Strategic Wealth LLC boosted its stake in shares of ADMA Biologics by 6.6% in the 1st quarter. Journey Strategic Wealth LLC now owns 17,820 shares of the biotechnology company’s stock valued at $354,000 after purchasing an additional 1,102 shares in the last quarter. Finally, KBC Group NV boosted its stake in shares of ADMA Biologics by 11.5% in the 1st quarter. KBC Group NV now owns 11,217 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 1,154 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

ADMA Biologics Stock Down 1.1%

Shares of NASDAQ ADMA opened at $17.44 on Wednesday. The firm’s 50-day simple moving average is $18.15 and its 200 day simple moving average is $18.87. The company has a market cap of $4.16 billion, a price-to-earnings ratio of 20.28 and a beta of 0.38. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21. ADMA Biologics Inc has a 12-month low of $13.50 and a 12-month high of $25.67.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.14 by $0.01. The firm had revenue of $121.98 million during the quarter, compared to analysts’ expectations of $121.77 million. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The company’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period in the previous year, the business posted $0.13 EPS. On average, research analysts expect that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on ADMA shares. Raymond James Financial boosted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a “strong-buy” rating in a research note on Thursday, May 8th. Wall Street Zen downgraded shares of ADMA Biologics from a “hold” rating to a “sell” rating in a research report on Friday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company’s stock. According to MarketBeat.com, ADMA Biologics has a consensus rating of “Buy” and a consensus target price of $27.67.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the business’s stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $20.96, for a total transaction of $419,200.00. Following the completion of the sale, the director directly owned 94,830 shares of the company’s stock, valued at approximately $1,987,636.80. The trade was a 17.42% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Steve Elms sold 194,749 shares of the company’s stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $20.24, for a total value of $3,941,719.76. Following the completion of the sale, the director directly owned 87,330 shares of the company’s stock, valued at approximately $1,767,559.20. This trade represents a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 456,842 shares of company stock valued at $9,486,200. 3.70% of the stock is currently owned by insiders.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.